Skip to Content

MenHibrix Approval History

MenHibrix (Hib-MenCY-TT) is a combination vaccine for the active immunization of infants and young children 6 weeks through 18 months of age for the prevention of invasive diseases caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b (Hib).

Development History and FDA Approval Process for MenHibrix

Jun 15, 2012Approval GSK Receives FDA Approval for MenHibrix
Dec  1, 2011Regulatory Update: Glaxosmithkline Submits Additional Information for Candidate Meningococcal and Hib Combination Vaccine
Sep 26, 2011Regulatory Update: GlaxoSmithKline Receives Complete Response Letter from FDA for MenHibrix meningococcal and Hib combination vaccine

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.